The Economic Burden of Severe Osteoporotic Fractures in the French Healthcare Database: The FRACTOS Study.
FRACTURE PREVENTION
GENERAL POPULATION STUDIES
HEALTH ECONOMICS
OSTEOPOROSIS
THERAPEUTICS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
21
09
2022
received:
21
04
2022
accepted:
22
09
2022
pubmed:
8
10
2022
medline:
28
10
2022
entrez:
7
10
2022
Statut:
ppublish
Résumé
Osteoporosis carries a high medical, economic, and societal burden principally because of the risk of severe fractures. The objective of this cost-of-illness study was to describe health resource utilization and associated costs in all patients aged ≥50 years hospitalized for a severe osteoporotic fracture over a 6-year period (2009 to 2014) in France. Data were extracted from the French national healthcare database (SNDS) on all health care resource utilization between the index date (date of hospitalization for first fracture during the enrollment period) and study end (December 31, 2016) or until the patient died. Costing was restricted to direct costs and determined from the payer perspective. Variables related to costs were identified through multivariate logistic regression analysis. A total of 356,895 patients were included (median follow-up 39.1 months). In the year after the index fracture, 36,622 patients (10.5%) were rehospitalized for a fracture-related reason. Only 18,474 (5.3%) underwent bone densitometry and 58,220 (16.7%) received a specific treatment. The total annual per capita osteoporosis-related cost in the year after the index severe osteoporotic fracture was €18,040 (from €8598 for multiple ribs to €21,085 for hip fracture) of which €17,905 was incurred by fracture-related costs. The cost incurred by management of osteoporosis was €135. Over years 2 to 5, the mean annual per capita costs of fracture treatment (€806, mostly attributable to the treatment of refractures) continued to dominate those of osteoporosis management (€99). Total annual cost of care was €1260 million (year 2014). Variables associated with higher cost were older age, male sex, site of fracture, a history of prior osteoporotic fracture, and the number of refracture events. The 5-year cost of severe osteoporotic fractures to the French health care system is high and mostly attributable to the treatment of refractures. Improved fracture prevention measures in patients with osteoporosis is crucial to reduce the economic burden of the disease. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Identifiants
pubmed: 36203366
doi: 10.1002/jbmr.4720
pmc: PMC9828635
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1811-1822Subventions
Organisme : UCB Pharma and Amgen, Inc
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Références
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
Arch Osteoporos. 2018 Sep 14;13(1):96
pubmed: 30218380
Osteoporos Int. 2022 Mar;33(3):625-635
pubmed: 34642813
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
Osteoporos Int. 2019 Jan;30(1):3-44
pubmed: 30324412
Bone. 2004 Aug;35(2):375-82
pubmed: 15268886
J Clin Pharmacol. 2016 Nov;56(11):1416-1422
pubmed: 26999526
Osteoporos Int. 2011 Jul;22(7):2083-98
pubmed: 21607809
Hong Kong Med J. 2018 Dec;24(6):579-583
pubmed: 30449735
Curr Opin Rheumatol. 2017 Jul;29(4):416-421
pubmed: 28426444
Osteoporos Int. 2005 Dec;16(12):1475-80
pubmed: 16217587
Osteoporos Int. 2011 Mar;22(3):967-82
pubmed: 20936401
Therapie. 2018 Feb;73(1):13-24
pubmed: 29530314
J Bone Miner Res. 2017 Feb;32(2):203-211
pubmed: 27632945
J Bone Miner Res. 2000 Apr;15(4):721-39
pubmed: 10780864
Bone. 2002 Apr;30(4):631-6
pubmed: 11934657
JAMA. 2009 Feb 4;301(5):513-21
pubmed: 19190316
Bone. 2010 Jul;47(1):34-40
pubmed: 20303422
JBMR Plus. 2021 May 14;5(7):e10507
pubmed: 34258503
Arch Osteoporos. 2020 Apr 19;15(1):59
pubmed: 32306163
Arch Osteoporos. 2020 Mar 13;15(1):46
pubmed: 32170512
Osteoporos Int. 2017 Dec;28(12):3289-3300
pubmed: 28770272
Joint Bone Spine. 2018 Oct;85(5):519-530
pubmed: 29654947
Clinicoecon Outcomes Res. 2015 Feb 09;7:105-17
pubmed: 25709480
Arch Cardiovasc Dis. 2016 Jun-Jul;109(6-7):399-411
pubmed: 27079468
Spine J. 2019 Mar;19(3):411-417
pubmed: 30142455
J Med Econ. 2011;14(1):53-64
pubmed: 21222506
Bone. 2021 Jan;142:115071
pubmed: 31593822
Osteoporos Int. 2019 Sep;30(9):1745-1754
pubmed: 31270592
Osteoporos Int. 2012 May;23(5):1623-9
pubmed: 21476038
Arch Osteoporos. 2013;8:136
pubmed: 24113837
Value Health. 2022 Apr;25(4):571-581
pubmed: 35365301
Clin Exp Rheumatol. 2012 Mar-Apr;30(2):222-7
pubmed: 22546070